Background
Patients treated with androgen withdrawal for advanced prostate cancer become refractory to this therapy within a median 18-24 months. Combination chemotherapy can improve symptoms in hormone-refractory prostate cancer, 1,2 and offers some survival benefit. 3, 4 However, cancer patients express a strong preference for oral rather than intravenous therapies. 5, 6 Short-lived prostate-specific antigen (PSA) responses are seen with prednisolone, estramustine and diethylstilboestrol, but these last two drugs are associated with significant thrombo-embolic toxicity. 7 Most patients remain asymptomatic for some months following detection of PSA rise after androgen withdrawal, so there is a clear need for a well tolerated, orally administered, disease-modifying therapy.
The fluoropyrimidine 5-fluorouracil (5FU), administered intravenously with or without folinic acid, produces few responses in hormone-refractory prostate cancer, at the expense of significant toxicity. [8] [9] [10] [11] [12] However, responses were seen using low-dose infusional 5FU. 13, 14 Capecitabine (Xeloda, Roche Products) is an orally administered fluoropyrimidine carbamate preferentially converted to 5-FU at sites of disease by thymidine phosphorylase expressed in tumour cells, 15 including prostate cancer cells. 16 Capecitabine is active in a number of tumour types including colorectal, breast, stomach and pancreatic cancer. In particular, capecitabine monotherapy is now well established as first-line treatment in advanced colorectal cancer, 17, 18 and as a preferred option in taxane-pretreated metastatic breast cancer. 19 Survival with the combination of capecitabine and docetaxel is superior to docetaxel alone in metastatic breast cancer. 20 There is anecdotal evidence of capecitabine activity in prostate cancer, 21 and we have conducted an open label phase II study to evaluate the efficacy and safety of this drug in patients with hormone-refractory prostate cancer. PSA response was chosen as the primary end point, according to published guidelines. 22 
Patients and methods

Study design
This open label, phase II, non-randomised single-centre study was designed to investigate the efficacy of capecitabine in prostate cancer patients with progressive disease despite androgen withdrawal. The study received ethical approval from the local ethics review committee, and all patients gave written, informed consent.
Patient eligibility
Eligible patients had histologically confirmed adenocarcinoma of the prostate with progression of locally advanced or metastatic disease despite androgen withdrawal with a luteinising hormone releasing hormone (LHRH) agonist. Disease progression was defined as a rise in serum PSA on two consecutive occasions at least 2 weeks apart. 22 Patients with measurable disease were also included.
Patients who had received prior chemotherapy were not eligible. Previous or concurrent radiotherapy was allowed. Patients were required to have a WHO performance status of 2 or less, and to have a life expectancy of at least 3 months. Those with significant weight loss or severe pain were excluded. Patients with inadequate haematological, renal or liver parameters (neutrophils o0.5 Â 10 9 /l, calculated creatinine clearance o50 ml/min, platelets o100 Â 10 9 /l, bilirubin 430), intracranial metastases or cord compression were also excluded. Other exclusion criteria included any concurrent medical condition or laboratory abnormality that could compromise the safety of the patient or interfere with the interpretation of the results.
Treatment regimen
Patients were treated with oral capecitabine 1250 mg/m 2 self-administered twice daily (2500 mg/m 2 /day), as intermittent therapy in 3-week cycles consisting of 14 days of treatment followed by 7 days without treatment. Details of the treatment regimen have been previously described. 23 Androgen withdrawal with an LHRH analogue was continued in all patients. Treatment was given if the neutrophil count exceeded 0.5 Â 10 9 /l, lymphocyte count exceeded 0.5 Â 10 9 /l and platelets were greater than 100 Â 10 9 /l. Adverse events were graded on a four-point scale (WHO common toxicity criteria), with an additional scale for hand-foot syndrome. Capecitabine was delayed and dosage reduced by 20% for treatment-related adverse events of grade 2 or greater. Patients were eligible to receive eight cycles, with the option to continue in the event of maintained response. Treatment was discontinued in the absence of PSA response or control (a fall in PSA velocity by 50% or more) after four cycles, on PSA progression subsequently, or on symptomatic deterioration.
Patient assessment and response criteria
Screening assessments, including a medical history, physical examination, full blood count and chemistry profile were performed within 1 week before treatment began. Serial rises in serum PSA, as above, were required before trial entry. PSA level and full blood count were repeated with each 21-day cycle. A PSA response was defined as a X50% decrease from baseline in serum PSA, determined by two observations not less than 4 weeks apart. PSA velocity was defined as the rate of change of the natural logarithm of PSA with time, and baseline PSA velocity was calculated using at least two pre-treatment PSA values for each patient. PSA stabilisation was defined as a fall in PSA velocity by 50% or more. Patients meeting neither of these criteria were considered to have progressive disease. For patients with measurable disease, radiological investigations were repeated after three cycles, or at biochemical or clinical progression. Response was assessed according to RECIST criteria, 24 with partial response defined as a X30% decrease from baseline.
Statistical methods
The aims of this phase II study were to assess the efficacy and toxicity of capecitabine in hormone refractory prostate cancer. The primary end point was response as assessed using serum PSA. Using a sequential analysis design, 25 the absence of a response among the first 14 patients would indicate insufficient study drug activity to warrant further study. Thus 14 assessable subjects were recruited.
The analysis of efficacy was based on all patients who received at least one dose of capecitabine. Similarly, safety was assessed for all patients who received at least one dose of the study drug.
Results
A total of 14 patients were enrolled in this study between July 2002 and November 2003. All patients completed at least one cycle of capecitabine and were assessable for response. All patients had progressed following LHRH therapy. The median PSA at study entry was 496 ng/ml, Study of oral capecitabine J Spicer et al and median ECOG performance status was one. Patient characteristics are summarised in Table 1. A total of 76 cycles of capecitabine were administered, and the median number of cycles was 5.4 (range 4-9). One cycle was delayed because of grade 3 toxicity (Hand-foot syndrome). 3 patients (21%) were withdrawn from the study because of toxicity.
Response and response duration
All 14 patients treated with capecitabine were assessed for response. The PSA profile for each patient is shown in Figure 1 . One patient had a PSA response, for an overall response rate of 7% (95% confidence interval 0-20%, Fisher's exact test). This partial response was confirmed on CT-imaging of liver metastases. PSA velocity fell in a further seven patients (50%) after starting capecitabine treatment (Figure 2) , giving a combined PSA control rate of 57%. The duration of PSA stabilisation was generally short (Figure 1 ), but in five patients (36%) was sustained beyond 18 weeks, and in one patient to 24 weeks.
Four patients (29%) experienced progressive disease or did not tolerate treatment within the first 12 weeks of capecitabine therapy and discontinued study medication.
Toxicity
All patients were assessed for toxicity. The most common toxicities were nausea, mucositis and hand-foot syndrome ( Table 2 ). The majority of toxicities were grade 1 or 2. Only grade 3 toxicity was hand-foot syndrome. There was no grade 4 toxicity and there were no toxicityrelated deaths. Five patients experienced grade 2 lymphopenia that did not require dose reduction or discontinuation of treatment. Other clinical laboratory values were stable, and did not worsen by more than one grade in any patient. Neutropenia requiring dose reduction or delay was not seen. No patients discontinued treatment because of abnormal laboratory values.
Conclusion
In this phase II study in hormone-refractory prostate cancer, one patient (7%) treated with capecitabine had a response as assessed by both PSA and CT imaging of liver metastases, a response rate broadly comparable with docetaxel-containing combination therapy. 3, 4 PSA velocity fell in a further eight patients (50%). Another study of capecitabine in hormone-refractory prostate cancer reported a PSA response rate of 12%. Figure 2 PSA velocity change. PSA velocity is defined as the ratio of rate of change in ln (post-treatment PSA) to the rate of change in ln (pretreatment PSA). Thus, a ratio below 1 implies a reduction in PSA velocity (PSA stabilisation), and a negative ratio suggests a reduction in PSA. Capecitabine is currently approved for the treatment of patients with several tumour types including breast and colorectal cancer, and has demonstrated good tolerability in clinical trials. The most frequent treatment-related adverse events in most trials were nausea, diarrhoea and hand-foot syndrome, with a low incidence of myelosuppression. Capecitabine was generally well tolerated in this study. The most common treatmentrelated adverse events were nausea, mucositis and handfoot syndrome, each occurring in 50% of patients. The only grade 3 or 4 toxicity was hand-foot syndrome, occurring in one patient. No treatment alteration was required for haematological toxicity.
The toxicity profile of capecitabine compares favourably with that previously reported for palliative chemotherapy in hormone-refractory prostate cancer. [1] [2] [3] [4] Grade 3 or 4 toxicity occurred in 35% of patients treated with mitoxantrone and prednisolone, and in 43-46% following docetaxel and prednisolone. 4 Capecitabine has the further significant advantage of oral administration.
The use of PSA as a surrogate for disease activity and response to treatment in prostate cancer is well validated. 27, 28 The assay is inexpensive and reproducible, and can provide a more objective assessment than imaging, because bone metastases predominate in many patients with advanced prostate cancer. PSA doubling time provides a useful means of monitoring progression of prostate cancer, 29 and thus reduction in doubling time following capecitabine treatment may predict clinical benefit.
The results of this small study suggest that capecitabine has some activity in hormone-refractory prostate cancer, based on PSA response and control rates of 7 and 64%, respectively. Toxicity was significant but manageable, and compares favourably with that of standard palliative chemotherapy regimens used in advanced prostate cancer. Experience with capecitabine in prostate cancer in Switzerland was associated with more severe toxicity, 26 including two treatment-related deaths, a distinction possibly accounted for by pharmacogenomic differences in the study populations. We observed acceptable levels of toxicity, and indications of efficacy suggest that further studies are required to evaluate the role of capecitabine in this disease.
